REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) — Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter of 2022 on Tuesday, November 8, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
New "GIM" method tops MIB global leaderboard, offering the industry a scalable way to inspect…
HOTWORX Shares Expert Guidance on Building Sustainable Fitness Goals That Go Beyond Just Working OutNEW…
Leading Dog Training Franchise Expands Human Level Fitness Tracking to Select LocationsLOS ANGELES, Dec. 18,…
AdventHealth's David Banks, Savannah Bananas' Tyler Gillum, AMA's John Whyte, MD, MPH and Lenox Hill…
Practice of the Year and Innovator of the Year honorees recognized for patient-centered care, operational…
As Chief Executive Officer of Alexso, Inc., a nationwide pharmaceutical distributor, Farahmand has earned recognition…